Drug Screening Project - ProRett 2024

Overview

Project Summary

Rett syndrome is a rare neurodevelopmental disorder caused by mutations in the MECP2 gene. Recently, Prof. Tongiorgi’s lab identified from a panel of FDA-approved drugs 13 compounds able to rescue aberrant neuronal morphology in cultured hippocampal RTT neurons. In this project, we aim at testing in vivo the effects of compounds D4 and D5 in rescuing emotional dysregulation using the Mecp2 mutant animals, a mouse model of Rett.

Main Goals

Aim 1: Test the effects of coumpounds D4 and D5 is rescuing anxiety, depressive-like and fear memory alterations in the Mecp2-mutant mice.

External Team

Prof. Enrico Tongiorgi, University of Trieste, Italy

Dr. Carmen Agustín-Pavón, University of Valencia, Spain

Partners

Funding

Project Details

Project Code

ProRETT Ricerca

Approval Date

2023-12-26

Start Date

2024-05-01

End Date

2025-04-30

Total Cost

20000,0€

We use cookies to improve your visit to our website.